Abstract. Squamous cell carcinoma is a rare histological type of breast cancer classified as metaplastic carcinoma. Metaplastic carcinoma involves differentiation of the breast glandular duct cells into mesenchymal tissues. While the chemotherapy regimen for metaplastic carcinoma is often similar to that for invasive ductal carcinoma, recurrence is associated with a poor prognosis due to the inadequate therapeutic efficacy of the regimen. We herein present the case of a 42-year-old female patient who underwent mastectomy of the right breast and right axillary node lymphadenectomy for T4N3aM0 breast cancer stage. The cancer was histopathologically diagnosed as squamous cell carcinoma of the breast. Adjuvant cyclophosphamide-epirubicin-fluorouracil (CEF) postoperative chemotherapy was administered, and lymphadenectomy of right-sided parasternal lymphatic metastases with pleural drainage was subsequently performed. Radiotherapy was administered to the thoracic wall and supraclavicular lymph nodes at 60 Gy. Positron emission tomography (PET)-computed tomography (CT) examination 3 months after the radiotherapy identified accumulation of fluorodeoxyglucose (FDG) in a supraclavicular lymph node and the thoracic wall; hence, a chemotherapeutic regimen with eribulin was initiated. At 11 months after initiation of eribulin, complete response was achieved, indicated by the absence of FDG accumulation in both the supraclavicular lymph node and the thoracic wall on PET-CT. The treatment efficacy of eribulin is considered to be a result of the mixed morphology of squamous cell carcinoma, including the presence of an epithelial component, such as adenocarcinoma cells, and a mesenchymal component, in the form of sarcomatoid cells. Eribulin displayed an effect similar to that of adriamycin against malignant soft tissue tumors and was shown to effectively target mesenchymal components. In cases of reduced expression of the DNA repair pathway components, such as in metaplastic carcinomas, eribulin may be more effective compared with adriamycin, the mechanism of action of which involves inhibition of DNA synthesis. A superior therapeutic effect was obtained with eribulin in squamous cell carcinoma. Therefore, eribulin appears to be a promising, effective therapeutic choice for the management of metaplastic carcinomas, including squamous cell carcinomas.
Introduction
Squamous cell carcinoma is a type of metaplastic carcinoma; metaplastic carcinoma is characterized as carcinoma of the breast ductal tissue and stratified squamous epithelial tissue followed by their consequent differentiation into bone, cartilage and osteocartilaginous tissue. It has been reported that metaplastic breast carcinoma accounts for <1% of all breast carcinomas, and it is characterized by large size, low incidence of lymphatic metastasis and high incidence of triplenegative phenotype (1-3). While chemotherapy for metaplastic carcinoma is commonly similar to that of invasive ductal carcinoma, a number of studies in the literature report a poor response to conventional chemotherapy (1, 4, 5) . We herein report our experience with eribulin administration in a case of recurrent squamous cell carcinoma of the breast and discuss the relevant literature.
Case report
A 42-year-old woman with carcinoma of the right breast (T4N3aM0, stage IIIC) underwent mastectomy and level III axillary lymph node dissection (Fig. 1) .
Pathological examination revealed squamous cell carcinoma negative for estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 (Fig. 2) . Six cycles of postoperative adjuvant chemotherapy with cyclophosphamide 500 mg/m 2 , epirubicin 75 mg/m 2 and fluorouracil 500 mg/m 2 (CEF regimen) were administered, following which an increase in the size of the ipsilateral sternal lymph nodes was observed. No other metastatic lesions were found on computed tomography (CT) scans, and the patient was subjected to lymphadenectomy with pleural drainage. Pathological examination of the resected nodes demonstrated metastatic squamous cell carcinoma. Docetaxel (75 mg/m 2 ) was administered as adjuvant therapy; however, allergic symptoms developed, including respiratory distress and palpitations, and docetaxel was discontinued. Radiotherapy to the right thoracic wall and the right supraclavicular lymph node (60 Gy) was next administered. However, enlargement of the ipsilateral supraclavicular lymph node was observed 3 months after radiotherapy. Lymphadenopathy (lymph node enlarged to 2 cm in diameter) was identified on ultrasound examination, and fine-needle aspiration cytology confirmed the presence of metastatic squamous cell carcinoma. Fluorodeoxyglucose positron emission tomography (FDG-PET)-CT revealed accumulation in the anterior thoracic wall close to the previous surgical site (Fig. 3) . Consequently, eribulin (1.4 mg/m 2 ) was administered as initial therapy. The lymph node was not palpable at 1 month after therapy initiation, and at 3 months after chemotherapy the enlargement had completely disappeared, as demonstrated on a CT examination. No metastatic lymph node or thoracic wall FDG accumulation was observed on PET-CT 11 months after treatment initiation (Fig. 4) . After 17 months of treatment, the patient remained metastasis-free. During those 17 months, no major side effects were observed although peripheral neuropathy not affecting daily life grade 1 peripheral neurotoxicity occurred.
Discussion
It is generally recommended that the protocols for the treatment of invasive ductal carcinoma of breast cancer are applied for the treatment of squamous cell carcinoma. However, poor efficacy of chemotherapy in recurrent carcinomas, including squamous cell carcinoma, has been reported to date. While previous studies have reported the use of anthracyclines and taxanes, to the best of our knowledge, there are yet no published reports on the efficacy of eribulin. We herein discuss the possible reasons for the observed effectiveness of eribulin in the treatment of metaplastic breast carcinoma.
In addition to its effectiveness against the epithelial component, it is possible that eribulin is also effective against the mesenchymal component of the carcinoma. Drug regimens including adriamycin, which is also indicated for soft tissue tumors with a mesenchymal component, have been reported to significantly prolong progression-free survival in metaplastic carcinomas compared with other regimens. Reduced incidence of hepatic metastasis has also been reported with the use of ifosfamide and etoposide, which are used for treating soft tissue tumors (6) . In Study 309, eribulin was found to be effective against liposarcoma or leiomyosarcoma (7). Eribulin promotes DNA repair, the inhibition of which is characteristic of metaplastic carcinomas, and is thus considered a more effective therapeutic agent compared with adriamycin, of which the primary mechanism of action involves the inhibition of DNA synthesis.
Furthermore, in metaplastic carcinomas, tumors including squamous epithelial and sarcomatous components exhibit increased expression of TWIST and SNAIL 2 transcription factors, suggesting an association with epithelial-tomesenchymal transition (EMT) (8, 9) . Reports indicate that the occurrence of EMT in cancer cells coincides with the development of resistance to various anticancer agents. Several anticancer agents have been reported to induce EMT and are considered to be involved in drug resistance. Albeit in an in vitro study, eribulin has been shown to inhibit Smad 2 and Smad 3 phosphorylation via transforming growth factor-β induction or MET inhibition. These characteristic mechanisms of action of eribulin are considered to contribute to the effectiveness of the therapy in the present case.
